Bandingkan metode
Tinjau metode pilihan Anda berdampingan; baris yang berbeda akan disorot.
| Routine Assessment of Patient Index Data 3 (RAPID3)× | Indeks Aktivitas Penyakit Sistemik Lupus Eritematosus 2000 (SLEDAI-2K)× | |
|---|---|---|
| Bidang | Reumatologi | Reumatologi |
| Keluarga | Process / pipeline | Process / pipeline |
| Tahun asal≠ | 2008 | 2002 |
| Pencetus≠ | Pincus et al. | Gladman et al. |
| Tipe≠ | Patient-reported outcome (PRO) | Clinician-rated |
| Sumber perintis≠ | Pincus T, Bergman MJ, Sokka T, Roth SH, Swearingen C, Yazici Y. Activity of rheumatoid arthritis is similar in patients seen in a primary care physician-based practice and in an academic rheumatology-based practice. Arthritis Care Research. 2008;59(9):1229-1236. link ↗ | Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291. link ↗ |
| Alias≠ | RAPID3, RAPID-3 | SLEDAI, SLEDAI-2K, SLE Disease Activity Index |
| Terkait | 3 | 3 |
| Ringkasan≠ | RAPID3 is a patient-reported outcome (PRO) measure of rheumatoid arthritis disease activity based on three simple self-report items: patient-counted swollen and tender joints and overall health assessment. Introduced by Pincus et al. in 2008, RAPID3 was designed for primary care and busy practices where joint examination is impractical or time-limited. Remarkably, RAPID3 correlates strongly with clinician-examined composite measures (DAS28, CDAI, SDAI) and predicts long-term radiographic progression equally well, making it a practical alternative for resource-limited settings and self-directed monitoring. | The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease. |
| ScholarGateSet data ↗ |
|
|